Sector News

Allergan buys Kythera and its double-chin drug for $2.1bn

June 17, 2015
Life sciences
Dublin, Ireland-based Allergan is snapping up US group Kythera Biopharmaceuticals for a cool $2.1 billion, strengthening the firm’s foothold on the facial aesthetics scene.
 
The move gives Allergan access to Kythera’s lead product Kybella (deoxycholic acid) injection, the first and only approved non-surgical treatment for double chin (or severe submental fullness), which gained US clearance in April.
 
The acquisition will also bring setipiprant (KYTH-105) – a novel compound for the prevention of male pattern baldness – into Allergan’s pipeline, as well as a batch of other early-stage development candidates.
 
Under the deal, which remains subject to customary closing conditions, the Irish drugmaker will pay $75 per Kythera share in a mix of cash and stock, valuing the transaction at around $2.1 billion.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend